VivoSim Labs, Inc. (NASDAQ:VIVS) shares are up on Wednesday as the company disclosed a significant milestone payment from Eli Lilly and Company (NYSE:LLY) and provided optimistic revenue guidance for FY2027.
The stock’s surge comes amid a broader market that is showing slight gains, with S&P 500 futures up 0.3%.
Eli Lilly Milestone Payment & Outlook
VivoSim Labs received a $5 million milestone payment from Eli Lilly after the first patient was dosed in a Phase 2 trial for its former inflammatory bowel disease drug program, now owned and developed by Lilly.
VivoSim remains eligible for up to $45 million in additional milestone payments tied to future regulatory and commercial milestones. The company also announced fiscal 2027 revenue guidance.
